<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="editorial" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">World J Methodol</journal-id><journal-id journal-id-type="pmc-domain-id">2552</journal-id><journal-id journal-id-type="pmc-domain">wjmethod</journal-id><journal-id journal-id-type="publisher-id">WJM</journal-id><journal-title-group><journal-title>World Journal of Methodology</journal-title></journal-title-group><issn pub-type="epub">2222-0682</issn><publisher><publisher-name>Baishideng Publishing Group Inc</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11612738</article-id><article-id pub-id-type="pmcid-ver">PMC11612738.1</article-id><article-id pub-id-type="pmcaid">11612738</article-id><article-id pub-id-type="pmcaiid">11612738</article-id><article-id pub-id-type="pmid">40548210</article-id><article-id pub-id-type="doi">10.5662/wjm.v15.i2.98912</article-id><article-id pub-id-type="other">jWJM.v15.i2.eid98912</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Editorial</subject></subj-group></article-categories><title-group><article-title>Enhancing the outcomes of diabetic vitrectomy with pharmacological adjuvants</article-title><alt-title>Cheng CY <italic toggle="yes">et al</italic>. Optimizing surgical outcomes with pharmacological adjuncts</alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Cheng</surname><given-names initials="CY">Chun-Yao</given-names></name><aff>Department of Ophthalmology, Cathay General Hospital, Taipei 10633, Taiwan</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hao</surname><given-names initials="WR">Wen-Rui</given-names></name><aff>Division of Cardiology, Department of Internal Medicine, Shuang Ho Hospital, Ministry of Health and Welfare, Taipei Medical University, New Taipei City 23561, Taiwan</aff><aff>Division of Cardiology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11002, Taiwan</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cheng</surname><given-names initials="TH">Tzu-Hurng</given-names></name><aff>Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, Taichung City 404328, Taiwan. <email>thcheng@mail.cmu.edu.tw</email></aff></contrib></contrib-group><author-notes><fn><p>Co-corresponding authors: Wen-Rui Hao and Tzu-Hurng Cheng.</p><p>Author contributions: Cheng CY and Hao WR contributed equally to this editorial, with both authors collaboratively drafting the initial content and structuring the editorial&#8217;s key messages. Hao WR and Cheng TH provided critical oversight during the revision process, ensuring the editorial accurately reflected recent advances in the field and maintained high scientific integrity. Cheng CY, Hao WR, and Cheng TH were actively involved in refining the content and enhancing the clarity of the argument. All authors read and approved the final manuscript. As co-corresponding authors, Hao WR and Cheng TH equally contributed to the editorial&#8217;s conceptual direction, revision process, and approval, ensuring the editorial&#8217;s alignment with the latest research and clinical practices.</p><p>Corresponding author: Tzu-Hurng Cheng, PhD, Professor, Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, No. 91 Xueshi Road, North District, Taichung City 404328, Taiwan. <email>thcheng@mail.cmu.edu.tw</email></p></fn></author-notes><pub-date pub-type="collection"><day>20</day><month>6</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>20</day><month>6</month><year>2025</year></pub-date><volume>15</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">476242</issue-id><elocation-id>98912</elocation-id><history><date date-type="received"><day>9</day><month>7</month><year>2024</year></date><date date-type="rev-recd"><day>11</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>23</day><month>10</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>20</day><month>06</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>20</day><month>06</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-06-24 15:25:17.200"><day>24</day><month>06</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169;The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="98912.pdf"/><abstract><p>This editorial offers insights from a minireview by Venkatesh <italic toggle="yes">et al</italic>, who explored pharmacological adjuvants for diabetic vitrectomy. Specifically, they synthesized current knowledge and evaluated the efficacy of various adjunctive therapies in improving the outcomes of diabetic retinopathy and managing associated complications. Herein, we highlight the key roles of pharmacological adjuvants in optimizing surgical techniques, minimizing intraoperative challenges, and enhancing postoperative recovery. We further discuss the potential implications of this approach for clinical practice and future research directions in this evolving field. Overall, this editorial underscores the importance of incorporating pharmacological adjuvants into standard diabetic vitrectomy care to improve surgical outcomes and thus patients&#8217; quality of life.</p></abstract><kwd-group><kwd>Diabetic vitrectomy</kwd><kwd>Pharmacological adjuvants</kwd><kwd>Surgical outcomes</kwd><kwd>Diabetic retinopathy</kwd><kwd>Clinical implications</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>
<bold>Core Tip:</bold> Incorporating pharmacological adjuvants into diabetic vitrectomy can significantly enhance surgical outcomes and postoperative recovery. These therapies reduce intraoperative complications like bleeding and improve surgical precision while minimizing postoperative issues, including inflammation and fibrosis. Therefore, the incorporation of these adjunctive treatments into routine clinical practice is crucial for improving patient care, lowering complication rates, and enhancing long-term visual outcomes for those undergoing diabetic vitrectomy.</p><sec><title>INTRODUCTION</title><p>The field of diabetic vitrectomy surgery is evolving with the introduction of pharmacological adjuvants, as highlighted by Venkatesh <italic toggle="yes">et al</italic>[<xref rid="B1" ref-type="bibr">1</xref>]. Diabetic retinopathy, a leading cause of global blindness, often requires vitrectomy to address complications such as vitreous hemorrhage and tractional retinal detachment. Traditional surgical techniques face challenges like intraoperative bleeding and postoperative complications[<xref rid="B1" ref-type="bibr">1</xref>-<xref rid="B3" ref-type="bibr">3</xref>]. Pharmacological adjuvants offer promising solutions by reducing bleeding, enhancing visualization, and promoting retinal healing[<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B5" ref-type="bibr">5</xref>]. Venkatesh <italic toggle="yes">et al</italic>[<xref rid="B1" ref-type="bibr">1</xref>] provided a comprehensive review of these therapies, evaluating their efficacy and safety, underscoring their potential to transform diabetic vitrectomy practices[<xref rid="B6" ref-type="bibr">6</xref>]. Integrating these advancements into clinical protocols could simplify surgery and improve patient outcomes globally[<xref rid="B7" ref-type="bibr">7</xref>,<xref rid="B8" ref-type="bibr">8</xref>]. This editorial synthesizes key insights from recent research, highlighting the transformative role of pharmacological adjuvants in diabetic vitrectomy and advocating for their integration into standard surgical practice[<xref rid="B9" ref-type="bibr">9</xref>,<xref rid="B10" ref-type="bibr">10</xref>].</p></sec><sec><title>CURRENT CHALLENGES IN DIABETIC VITRECTOMY</title><p>Diabetic vitrectomy presents numerous challenges due to the complex pathology of diabetic retinopathy. A major issue is intraoperative bleeding, which obscures the surgical field and increases the risk of complications[<xref rid="B2" ref-type="bibr">2</xref>]. The presence of fibrovascular membranes adds further complexity, requiring delicate dissection to minimize retinal damage[<xref rid="B4" ref-type="bibr">4</xref>]. Incomplete vitreous clearance also remains a significant concern, contributing to postoperative complications like proliferative vitreoretinopathy (PVR) and macular edema[<xref rid="B3" ref-type="bibr">3</xref>]. Traditional surgical techniques, while effective, are limited in addressing these issues. Studies have demonstrated that preoperative anti-vascular endothelial growth factor (anti-VEGF) agents, such as ranibizumab, reduce intraoperative bleeding by decreasing neovascularization in fibrovascular membranes[<xref rid="B6" ref-type="bibr">6</xref>]. Enzymatic vitreolysis using reengineered collagenases offers an innovative method for improving vitreous clearance, reducing the need for mechanical manipulation[<xref rid="B4" ref-type="bibr">4</xref>]. Also, <italic toggle="yes">in situ</italic> cross-linked hyaluronan hydrogel shows promise in facilitating posterior vitreous detachment, aiding in vitreous removal[<xref rid="B5" ref-type="bibr">5</xref>]. Pharmacological adjuvants like mitomycin C have also been explored for their potential to prevent postoperative fibrosis and PVR, improving both functional and anatomical outcomes[<xref rid="B3" ref-type="bibr">3</xref>]. High-density silicone oil is another approach used to manage severe proliferative diabetic retinopathy (PDR), though it carries risks such as increased intraocular pressure[<xref rid="B11" ref-type="bibr">11</xref>]. Despite these advances, significant challenges remain in diabetic vitrectomy. The integration of pharmacological adjuvants and innovative surgical techniques is crucial for improving outcomes and reducing postoperative complications. As research progresses, combining traditional methods with emerging therapies will likely enhance the safety and efficacy of diabetic vitrectomy[<xref rid="B1" ref-type="bibr">1</xref>].</p></sec><sec><title>ROLE OF PHARMACOLOGICAL ADJUVANTS</title><p>Pharmacological adjuvants play a crucial role in enhancing the efficacy of diabetic vitrectomy by addressing both intraoperative and postoperative challenges. Anti-VEGF agents, such as ranibizumab and bevacizumab, have proven effective in reducing intraoperative bleeding and facilitating the removal of fibrovascular membranes, both essential for successful outcomes in patients with PDR. These agents inhibit neovascularization, improving intraoperative visualization and reducing the risk of postoperative vitreous hemorrhage[<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B6" ref-type="bibr">6</xref>]. Preoperative anti-VEGF administration also appears to mitigate the angiogenic and fibrotic responses associated with diabetic retinopathy, enabling more precise and safer surgeries[<xref rid="B2" ref-type="bibr">2</xref>]. Corticosteroids, particularly dexamethasone implants, play a pivotal role in controlling postoperative inflammation, which accelerates patient recovery. Their anti-inflammatory effects help minimize the risk of macular edema and fibrosis, thus improving both functional and anatomical outcomes[<xref rid="B12" ref-type="bibr">12</xref>]. Mitomycin C, an antifibrotic agent, has also been shown to reduce the risk of PVR, improving surgical outcomes in cases of severe tractional retinal detachment[<xref rid="B3" ref-type="bibr">3</xref>]. Enzymatic vitreolysis is another innovative approach in diabetic vitrectomy. Reengineered collagenases, such as those derived from <italic toggle="yes">Vibrio mimicus</italic>, facilitate vitreous liquefaction, simplifying its removal and reducing the need for mechanical manipulation. This approach lowers the risk of retinal tears and postoperative complications[<xref rid="B4" ref-type="bibr">4</xref>]. Alike, cross-linked hyaluronan hydrogels have been explored to ease posterior vitreous detachment, further improving surgical efficiency[<xref rid="B5" ref-type="bibr">5</xref>]. As well, novel therapies like fibrin glue show promise in reducing the risk of postoperative vitreous hemorrhage, a common complication after diabetic vitrectomy. By promoting clot stabilization and reducing intraocular bleeding, fibrin glue contributes to better surgical outcomes[<xref rid="B13" ref-type="bibr">13</xref>]. Overall, the integration of pharmacological adjuvants in diabetic vitrectomy not only enhances surgical precision but also improves patient outcomes by addressing the complexities of diabetic retinopathy. As research continues to advance, the role of these adjuvants in clinical practice will likely expand, offering new avenues for improving the management of diabetic eye disease[<xref rid="B1" ref-type="bibr">1</xref>].</p></sec><sec><title>EVIDENCE FROM RECENT STUDIES</title><p>Recent studies have deepened our understanding of the role pharmacological adjuvants play in improving outcomes in diabetic vitrectomy. Venkatesh <italic toggle="yes">et al</italic>[<xref rid="B1" ref-type="bibr">1</xref>] provided comprehensive evidence on the efficacy and safety of these adjuncts in vitrectomy for diabetic retinopathy. Their research highlighted significant improvements in surgical success rates, visual acuity, and reductions in complications compared to traditional methods without adjuvants, underscoring the potential of these agents to mitigate the complexities of diabetic retinopathy surgery and enhance patient care. Similarly, Fadakar <italic toggle="yes">et al</italic>[<xref rid="B2" ref-type="bibr">2</xref>] investigated the effects of preoperative anti-VEGF treatment on fibrovascular membranes in patients with PDR. Their study found that anti-VEGF therapy not only reduces intraoperative bleeding but also modulates the angiogenic and fibrotic environment, contributing to more successful surgical outcomes. This aligns with the findings of Gao <italic toggle="yes">et al</italic>[<xref rid="B6" ref-type="bibr">6</xref>], who demonstrated the benefits of combining intravitreal ranibizumab with vitrectomy, particularly in cases involving neovascular glaucoma and diabetic vitreous hemorrhage. These therapies have been linked to improved anatomical and functional outcomes, further validating their role in enhancing surgical precision and reducing postoperative complications. Santra <italic toggle="yes">et al</italic>[<xref rid="B4" ref-type="bibr">4</xref>] explored enzymatic vitreolysis with collagenase to facilitate vitreous detachment in diabetic patients, showing promise in simplifying the surgical process. Building on this, Hisatomi <italic toggle="yes">et al</italic>[<xref rid="B5" ref-type="bibr">5</xref>] developed <italic toggle="yes">in situ</italic> cross-linked hyaluronan hydrogels, which aid in removing the posterior vitreous cortex, reducing the complexity of diabetic vitrectomy. Further supporting the use of pharmacological adjuvants, Gurelik <italic toggle="yes">et al</italic>[<xref rid="B3" ref-type="bibr">3</xref>] demonstrated that mitomycin C improves both functional and anatomical outcomes in patients with severe diabetic tractional retinal detachment, a challenging complication of PDR. Collectively, these studies underscore the importance of integrating pharmacological adjuvants into diabetic vitrectomy practice. These agents not only enhance surgical success rates and improve patient outcomes but also reduce the risk of complications such as recurrent hemorrhage and fibrosis. However, continued research is needed to fully elucidate their long-term benefits and refine optimal protocols for their use in clinical settings.</p></sec><sec><title>CLINICAL IMPLICATIONS AND ADOPTION CHALLENGES</title><p>Pharmacological adjuvants in diabetic vitrectomy have shown significant potential in improving surgical outcomes. Agents like anti-VEGF therapies (<italic toggle="yes">e.g.</italic>, ranibizumab and conbercept) and enzymatic vitreolysis agents help reduce intraoperative complications by facilitating the removal of fibrovascular membranes and controlling bleeding[<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B2" ref-type="bibr">2</xref>]. However, several challenges hinder their widespread adoption in clinical practice. One of the main barriers is the high cost associated with these treatments. Anti-VEGF medications are expensive, raising concerns about cost-effectiveness, particularly in regions with limited healthcare resources[<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B6" ref-type="bibr">6</xref>]. This financial burden restricts access for many patients, making it crucial for healthcare providers to balance the benefits of these therapies against their costs. As well, variability in efficacy across patient populations presents another challenge. While anti-VEGF agents improve outcomes for many, their effectiveness can depend on factors such as the timing of administration and disease severity[<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B8" ref-type="bibr">8</xref>]. For instance, preoperative anti-VEGF injections significantly reduce intraoperative bleeding in patients with PDR[<xref rid="B2" ref-type="bibr">2</xref>], but outcomes may vary based on individual patient characteristics. This variability necessitates a personalized approach, complicating efforts to standardize these treatments in clinical practice. A further concern is the lack of comprehensive long-term safety data. While short-term studies show promising results, particularly in reducing postoperative complications like macular edema, the long-term effects of repeated anti-VEGF injections or enzymatic vitreolysis remain under investigation[<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B14" ref-type="bibr">14</xref>]. There are concerns about potential adverse outcomes, including an increased risk of fibrosis or retinal detachment, which complicates the adoption of these therapies without more extensive evidence. Regulatory challenges also contribute to the slow adoption of newer pharmacological adjuvants, such as hyaluronan-based hydrogels. Issues with approval and regional availability make it difficult to integrate these therapies into routine care[<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B7" ref-type="bibr">7</xref>]. Healthcare providers must navigate these regulatory landscapes while staying updated on emerging pharmacological options to ensure the best care for their patients. To address these challenges, further research is essential. Ongoing clinical trials and studies are critical for refining treatment protocols, optimizing dosing strategies, and clarifying the long-term safety profiles of adjuvant therapies[<xref rid="B1" ref-type="bibr">1</xref>]. Large-scale, multicenter studies could help mitigate the variability in treatment outcomes and provide more definitive evidence to support broader adoption[<xref rid="B3" ref-type="bibr">3</xref>]. Additionally, developing cost-effective models and securing wider regulatory approval for innovative agents could enhance their clinical utility. Overall, while pharmacological adjuvants hold great promise in diabetic vitrectomy, their integration into routine practice faces barriers related to cost, variable efficacy and safety concerns. Ongoing research, along with collaborative efforts between clinicians, researchers and policymakers, is crucial to overcoming these challenges and ensuring that patients benefit from these advancements in diabetic retinopathy management.</p></sec><sec><title>FUTURE DIRECTIONS AND RESEARCH OPPORTUNITIES</title><p>The future of pharmacological adjuvants in diabetic vitrectomy is set to advance significantly through a comprehensive research strategy. A key focus will be refining existing therapies while exploring new agents and combination treatments to address the complexities of diabetic retinopathy. For example, ongoing work with hyaluronan-based hydrogels aims to simplify posterior vitreous cortex removal, potentially improving surgical outcomes[<xref rid="B5" ref-type="bibr">5</xref>]. Equally, research into reengineered collagenase demonstrates the promise of enzymatic vitreolysis for safer, more effective procedures[<xref rid="B4" ref-type="bibr">4</xref>]. Future studies should emphasize long-term efficacy and safety, particularly concerning outcomes like recurrence rates and visual stability. Randomized clinical trials will be critical in assessing the sustained benefits of preoperative anti-VEGF injections and other adjuvants, with early data suggesting reductions in intraoperative complications and postoperative inflammation[<xref rid="B2" ref-type="bibr">2</xref>]. Large-scale comparisons of agents like conbercept and ranibizumab are also needed to establish standardized protocols for different stages of diabetic retinopathy[<xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B8" ref-type="bibr">8</xref>]. Moreover, research should explore the integration of pharmacological adjuvants with emerging surgical techniques. Combination therapies, such as intravitreal steroids with vitrectomy, could enhance both anatomical and functional outcomes by mitigating postoperative complications like macular edema[<xref rid="B15" ref-type="bibr">15</xref>]. Furthermore, the use of mitomycin C in conjunction with vitrectomy for severe tractional retinal detachment shows potential for improving functional results[<xref rid="B3" ref-type="bibr">3</xref>]. Another important area for research is the assessment of quality-of-life measures and patient-reported outcomes. Since diabetic retinopathy often requires long-term management and multiple interventions, understanding how pharmacological adjuvants affect patients&#8217; daily lives and overall satisfaction is essential. Incorporating these patient-centered outcomes into clinical trials will guide treatment decisions and ensure that new therapies align with patient needs and expectations[<xref rid="B1" ref-type="bibr">1</xref>]. To drive these innovations, interdisciplinary collaboration is crucial. Partnerships between ophthalmologists, pharmacologists and bioengineers will accelerate the development of advanced drug delivery systems and more effective adjuvants. Such collaboration will ensure a holistic approach to diabetic vitrectomy, moving the field toward more personalized and patient-centered care[<xref rid="B7" ref-type="bibr">7</xref>]. In brief, advancing the role of pharmacological adjuvants in diabetic vitrectomy requires robust clinical research and cross-disciplinary innovation. By focusing on long-term efficacy, personalized treatment approaches, and enhancing patient-reported outcomes, the field can improve the surgical management of diabetic retinopathy, ultimately delivering better visual outcomes and quality of life for patients.</p></sec><sec><title>CONCLUSION</title><p>The integration of pharmacological adjuvants into diabetic vitrectomy surgery marks a significant advancement in enhancing surgical outcomes and elevating patient care standards. As detailed, these adjunctive therapies effectively address critical challenges such as intraoperative bleeding, postoperative inflammation and complications associated with diabetic retinopathy (Table <xref rid="T1" ref-type="table">1</xref>). The comprehensive review by Venkatesh <italic toggle="yes">et al</italic>[<xref rid="B1" ref-type="bibr">1</xref>] substantiates their efficacy and safety, providing a strong foundation for their strategic implementation in clinical practice[<xref rid="B6" ref-type="bibr">6</xref>]. Looking ahead, healthcare providers must navigate the challenges of adopting these therapies while leveraging evolving evidence to tailor treatment strategies that effectively meet individual patient needs. Continued research efforts are crucial for refining existing adjuvants, exploring novel therapeutic avenues, and establishing comprehensive guidelines for their optimal use[<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B16" ref-type="bibr">16</xref>]. Longitudinal studies focusing on long-term outcomes and patient-reported quality of life will further enhance clinical decision-making in this evolving field. In conclusion, incorporating pharmacological adjuvants into diabetic vitrectomy protocols holds great promise for significantly improving surgical outcomes and ultimately enhancing the quality of life for patients with diabetic retinopathy. By embracing these advancements, healthcare providers can achieve superior visual outcomes and effectively alleviate the global burden of diabetic eye disease[<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B8" ref-type="bibr">8</xref>].</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><p>Comparison of novel and traditional treatment modalities for diabetic retinopathy: Advantages and disadvantages</p></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="1" colspan="1">
<bold>Treatment modality</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>Advantages</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>Disadvantages</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>Ref.</bold>
<hr/>
</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">Novel: Pharmacological adjuvants in vitrectomy</td><td rowspan="1" colspan="1">Enhances vitreous clarity, improving surgical visibility; mitomycin C and other agents can improve functional outcomes</td><td rowspan="1" colspan="1">Adverse effects such as retinal toxicity in some cases; not universally adopted</td><td rowspan="1" colspan="1">Venkatesh <italic toggle="yes">et al</italic>[<xref rid="B1" ref-type="bibr">1</xref>], 2024; Gurelik <italic toggle="yes">et al</italic>[<xref rid="B3" ref-type="bibr">3</xref>], 2024</td></tr><tr><td rowspan="1" colspan="1">Novel: Anti-VEGF therapy</td><td rowspan="1" colspan="1">Reduces neovascularization and macular edema; short-term reduction in angiogenic and fibrotic factors in fibrovascular membranes</td><td rowspan="1" colspan="1">Requires repeated injections; potential ocular pain with multiple intravitreal injections</td><td rowspan="1" colspan="1">Fadakar <italic toggle="yes">et al</italic>[<xref rid="B2" ref-type="bibr">2</xref>], 2024; Zhou <italic toggle="yes">et al</italic>[<xref rid="B14" ref-type="bibr">14</xref>], 2024; Damasceno <italic toggle="yes">et al</italic>[<xref rid="B17" ref-type="bibr">17</xref>], 2024</td></tr><tr><td rowspan="1" colspan="1">Novel: Hyaluronan hydrogel adjuvant in vitrectomy</td><td rowspan="1" colspan="1">Facilitates easier removal of posterior vitreous cortex; biocompatible and injectable, improving surgical outcomes</td><td rowspan="1" colspan="1">Still under clinical evaluation; potential complications in certain patients</td><td rowspan="1" colspan="1">Hisatomi <italic toggle="yes">et al</italic>[<xref rid="B5" ref-type="bibr">5</xref>], 2024; Suzuki <italic toggle="yes">et al</italic>[<xref rid="B7" ref-type="bibr">7</xref>], 2023</td></tr><tr><td rowspan="1" colspan="1">Novel: Conbercept and ranibizumab pre-vitrectomy</td><td rowspan="1" colspan="1">Enhances anatomical outcomes by reducing vitreous hemorrhage; improves outcomes in complex cases such as neovascular glaucoma</td><td rowspan="1" colspan="1">Costly and not universally accessible; timing of administration critical for efficacy</td><td rowspan="1" colspan="1">Gao <italic toggle="yes">et al</italic>[<xref rid="B6" ref-type="bibr">6</xref>], 2023; Yang <italic toggle="yes">et al</italic>[<xref rid="B8" ref-type="bibr">8</xref>], 2023; Wang <italic toggle="yes">et al</italic>[<xref rid="B16" ref-type="bibr">16</xref>], 2023</td></tr><tr><td rowspan="1" colspan="1">Traditional: Laser photocoagulation</td><td rowspan="1" colspan="1">Well-established, reduces risk of vision loss from proliferative diabetic retinopathy</td><td rowspan="1" colspan="1">Can cause permanent retinal scarring; limited effect on macular edema</td><td rowspan="1" colspan="1">Venkatesh <italic toggle="yes">et al</italic>[<xref rid="B1" ref-type="bibr">1</xref>], 2024; Chauhan <italic toggle="yes">et al</italic>[<xref rid="B18" ref-type="bibr">18</xref>], 2024</td></tr><tr><td rowspan="1" colspan="1">Traditional: Pars plana vitrectomy</td><td rowspan="1" colspan="1">Effective in treating advanced proliferative diabetic retinopathy; can remove vitreous hemorrhage and fibrovascular tissue</td><td rowspan="1" colspan="1">High risk of complications, including postoperative vitreous hemorrhage; prolonged recovery period</td><td rowspan="1" colspan="1">Mansour <italic toggle="yes">et al</italic>[<xref rid="B13" ref-type="bibr">13</xref>], 2023; Rohowetz <italic toggle="yes">et al</italic>[<xref rid="B19" ref-type="bibr">19</xref>], 2024; Thapa <italic toggle="yes">et al</italic>[<xref rid="B20" ref-type="bibr">20</xref>], 2024</td></tr><tr><td rowspan="1" colspan="1">Traditional: Intravitreal steroids</td><td rowspan="1" colspan="1">Reduces inflammation and macular edema; long-lasting effect compared to anti-VEGF</td><td rowspan="1" colspan="1">Increases risk of intraocular pressure elevation; risk of cataract formation</td><td rowspan="1" colspan="1">Salvetat <italic toggle="yes">et al</italic>[<xref rid="B12" ref-type="bibr">12</xref>], 2024; Wang <italic toggle="yes">et al</italic>[<xref rid="B15" ref-type="bibr">15</xref>], 2024</td></tr></tbody></table><table-wrap-foot><fn><p>This table compares the advantages and disadvantages of novel and traditional treatments for diabetic retinopathy. Novel therapies, including pharmacological adjuvants and anti-vascular endothelial growth factor agents, offer advancements in managing complications but may involve higher costs and specific risks. Traditional approaches, such as laser photocoagulation and pars plana vitrectomy, remain effective but have limitations, including retinal scarring and extended recovery times. References are provided for further review of the supporting evidence. VEGF: Vascular endothelial growth factor.</p></fn></table-wrap-foot></table-wrap></sec></body><back><fn-group><fn fn-type="COI-statement"><p>
<bold>Conflict-of-interest statement:</bold> All the authors report no relevant conflicts of interest for this article.</p></fn><fn><p>
<bold>Provenance and peer review:</bold> Invited article; Externally peer reviewed.</p></fn><fn><p>
<bold>Peer-review model:</bold> Single blind</p></fn><fn><p>
<bold>Specialty type:</bold> Medical laboratory technology</p></fn><fn><p>
<bold>Country of origin:</bold> Taiwan</p></fn><fn><p>
<bold>Peer-review report&#8217;s classification</bold>
</p></fn><fn><p>
<bold>Scientific Quality:</bold> Grade B</p></fn><fn><p>
<bold>Novelty:</bold> Grade B</p></fn><fn><p>
<bold>Creativity or Innovation:</bold> Grade B</p></fn><fn><p>
<bold>Scientific Significance:</bold> Grade B</p></fn><fn><p>
<bold>P-Reviewer:</bold> Alhamood M <bold>S-Editor:</bold> Wei YF <bold>L-Editor:</bold> A <bold>P-Editor:</bold> Guo X</p></fn></fn-group><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Venkatesh</surname><given-names>R</given-names></name><name name-style="western"><surname>Jayadev</surname><given-names>C</given-names></name><name name-style="western"><surname>Prabhu</surname><given-names>V</given-names></name><name name-style="western"><surname>Gandhi</surname><given-names>P</given-names></name><name name-style="western"><surname>Kathare</surname><given-names>R</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>NK</given-names></name><name name-style="western"><surname>Choudhary</surname><given-names>A</given-names></name><name name-style="western"><surname>Chhablani</surname><given-names>J</given-names></name></person-group><article-title>Pharmacological adjuvants for diabetic vitrectomy surgery</article-title><source>World J Methodol</source><year>2024</year><volume>14</volume><pub-id pub-id-type="doi" assigning-authority="pmc">10.5662/wjm.v14.i4.92246</pub-id><pub-id pub-id-type="pmcid">PMC11287545</pub-id><pub-id pub-id-type="pmid">39712567</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fadakar</surname><given-names>K</given-names></name><name name-style="western"><surname>Rahmani</surname><given-names>S</given-names></name><name name-style="western"><surname>Tedeschi</surname><given-names>T</given-names></name><name name-style="western"><surname>Lavine</surname><given-names>JA</given-names></name><name name-style="western"><surname>Fawzi</surname><given-names>AA</given-names></name></person-group><article-title>Short Term Effect of Pre-Operative Anti-VEGF on Angiogenic and Fibrotic Profile of Fibrovascular Membranes of Proliferative Diabetic Retinopathy</article-title><source>Invest Ophthalmol Vis Sci</source><year>2024</year><volume>65</volume><fpage>37</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1167/iovs.65.4.37</pub-id><pub-id pub-id-type="pmcid">PMC11044842</pub-id><pub-id pub-id-type="pmid">38652648</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gurelik</surname><given-names>IG</given-names></name><name name-style="western"><surname>Ozdemir</surname><given-names>HB</given-names></name><name name-style="western"><surname>Acar</surname><given-names>B</given-names></name></person-group><article-title>The effect of adjuvant Mitomycin C during vitrectomy on functional and anatomical outcomes in patients with severe diabetic tractional retinal detachment</article-title><source>Int Ophthalmol</source><year>2024</year><volume>44</volume><fpage>210</fpage><pub-id pub-id-type="pmid">38691217</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10792-024-03152-3</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santra</surname><given-names>M</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>M</given-names></name><name name-style="western"><surname>Katoch</surname><given-names>D</given-names></name><name name-style="western"><surname>Jain</surname><given-names>S</given-names></name><name name-style="western"><surname>Saikia</surname><given-names>UN</given-names></name><name name-style="western"><surname>Dogra</surname><given-names>MR</given-names></name><name name-style="western"><surname>Luthra-Guptasarma</surname><given-names>M</given-names></name></person-group><article-title>Enzymatic vitreolysis using reengineered Vibrio mimicus-derived collagenase</article-title><source>Mol Vis</source><year>2021</year><volume>27</volume><fpage>125</fpage><lpage>141</lpage><pub-id pub-id-type="pmid">33907368</pub-id><pub-id pub-id-type="pmcid">PMC8056467</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hisatomi</surname><given-names>T</given-names></name><name name-style="western"><surname>Tachibana</surname><given-names>T</given-names></name><name name-style="western"><surname>Mori</surname><given-names>K</given-names></name><name name-style="western"><surname>Ishikawa</surname><given-names>K</given-names></name><name name-style="western"><surname>Ishibashi</surname><given-names>T</given-names></name><name name-style="western"><surname>Sonoda</surname><given-names>KH</given-names></name><name name-style="western"><surname>Uchio</surname><given-names>E</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>I</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>K</given-names></name><name name-style="western"><surname>Iida</surname><given-names>M</given-names></name></person-group><article-title>Injectable in situ cross-linking hyaluronan hydrogel for easier removal of posterior vitreous cortex in vitrectomy</article-title><source>Jpn J Ophthalmol</source><year>2024</year><volume>68</volume><fpage>146</fpage><lpage>156</lpage><pub-id pub-id-type="pmid">38311687</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10384-023-01039-x</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>S</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shen</surname><given-names>X</given-names></name></person-group><article-title>Clinical Efficacy of Preoperative and Intraoperative Intravitreal Ranibizumab as Adjuvant Therapy of Ahmed Glaucoma Valve Implantation Combined with Vitrectomy in the Management of Neovascular Glaucoma with Diabetic Vitreous Hemorrhage</article-title><source>J Pers Med</source><year>2023</year><volume>14</volume><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jpm14010018</pub-id><pub-id pub-id-type="pmcid">PMC10821123</pub-id><pub-id pub-id-type="pmid">38248719</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suzuki</surname><given-names>K</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>I</given-names></name><name name-style="western"><surname>Tachibana</surname><given-names>T</given-names></name><name name-style="western"><surname>Mori</surname><given-names>K</given-names></name><name name-style="western"><surname>Ishikawa</surname><given-names>K</given-names></name><name name-style="western"><surname>Ishibashi</surname><given-names>T</given-names></name><name name-style="western"><surname>Uchio</surname><given-names>E</given-names></name><name name-style="western"><surname>Sonoda</surname><given-names>KH</given-names></name><name name-style="western"><surname>Hisatomi</surname><given-names>T</given-names></name></person-group><article-title>Development of in situ crosslinked hyaluronan as an adjunct to vitrectomy surgery</article-title><source>J Mater Sci Mater Med</source><year>2023</year><volume>34</volume><fpage>56</fpage><pub-id pub-id-type="pmid">37930485</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10856-023-06757-9</pub-id><pub-id pub-id-type="pmcid">PMC10628021</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Di</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ye</surname><given-names>J</given-names></name><name name-style="western"><surname>Yu</surname><given-names>W</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Z</given-names></name></person-group><article-title>Comparison of the adjuvant effect of conbercept intravitreal injection at different times before vitrectomy for proliferative diabetic retinopathy</article-title><source>Front Endocrinol (Lausanne)</source><year>2023</year><volume>14</volume><fpage>1171628</fpage><pub-id pub-id-type="pmid">37305048</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fendo.2023.1171628</pub-id><pub-id pub-id-type="pmcid">PMC10254397</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schulz</surname><given-names>A</given-names></name><name name-style="western"><surname>Wakili</surname><given-names>P</given-names></name><name name-style="western"><surname>Januschowski</surname><given-names>K</given-names></name><name name-style="western"><surname>Heinz</surname><given-names>WR</given-names></name><name name-style="western"><surname>Engelhard</surname><given-names>M</given-names></name><name name-style="western"><surname>Menz</surname><given-names>H</given-names></name><name name-style="western"><surname>Szurman</surname><given-names>P</given-names></name></person-group><article-title>Safety and performance assessment of hyaluronic acid-based vitreous substitutes in patients with phthisis bulbi</article-title><source>Acta Ophthalmol</source><year>2023</year><volume>101</volume><fpage>687</fpage><lpage>695</lpage><pub-id pub-id-type="pmid">36912796</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/aos.15658</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>A</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L</given-names></name><name name-style="western"><surname>Bloom</surname><given-names>S</given-names></name><name name-style="western"><surname>Stanga</surname><given-names>P</given-names></name><name name-style="western"><surname>Figueroa</surname><given-names>MS</given-names></name><name name-style="western"><surname>Govetto</surname><given-names>A</given-names></name><name name-style="western"><surname>Mirajkar</surname><given-names>A</given-names></name><name name-style="western"><surname>Nagpal</surname><given-names>M</given-names></name><name name-style="western"><surname>Mehrotra</surname><given-names>N</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>A</given-names></name><name name-style="western"><surname>Rezaei</surname><given-names>KA</given-names></name></person-group><article-title>RWC Update: Intraoperative Fluorescein Angiography, Plasma Rich in Growth Factor as Adjuvant to Vitrectomy in High Myopic Retinal Detachment Associated With Full-Thickness Macular Hole, Giant Tear of the Retinal Pigment Epithelium</article-title><source>Ophthalmic Surg Lasers Imaging Retina</source><year>2023</year><volume>54</volume><fpage>259</fpage><lpage>264</lpage><pub-id pub-id-type="pmid">37184990</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3928/23258160-20230412-01</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Dwairi</surname><given-names>R</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>AA</given-names></name><name name-style="western"><surname>Aleshawi</surname><given-names>A</given-names></name><name name-style="western"><surname>Bani-Salameh</surname><given-names>AA</given-names></name><name name-style="western"><surname>Aljarrah</surname><given-names>IA</given-names></name><name name-style="western"><surname>Al-Bataineh</surname><given-names>QM</given-names></name><name name-style="western"><surname>Al</surname><given-names>Beiruti S</given-names></name><name name-style="western"><surname>Alshami</surname><given-names>AO</given-names></name><name name-style="western"><surname>Rusen</surname><given-names>E</given-names></name><name name-style="western"><surname>Toader</surname><given-names>G</given-names></name></person-group><article-title>Silicone Oil Utilized in Pars Plana Vitrectomy for Patients with Advanced Proliferative Diabetic Retinopathy: Physico-Chemical and Optical Properties</article-title><source>Clin Ophthalmol</source><year>2023</year><volume>17</volume><fpage>3719</fpage><lpage>3728</lpage><pub-id pub-id-type="pmid">38084208</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/OPTH.S447099</pub-id><pub-id pub-id-type="pmcid">PMC10710780</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salvetat</surname><given-names>ML</given-names></name><name name-style="western"><surname>Pellegrini</surname><given-names>F</given-names></name><name name-style="western"><surname>Spadea</surname><given-names>L</given-names></name><name name-style="western"><surname>Salati</surname><given-names>C</given-names></name><name name-style="western"><surname>Musa</surname><given-names>M</given-names></name><name name-style="western"><surname>Gagliano</surname><given-names>C</given-names></name><name name-style="western"><surname>Zeppieri</surname><given-names>M</given-names></name></person-group><article-title>The Treatment of Diabetic Retinal Edema with Intravitreal Steroids: How and When</article-title><source>J Clin Med</source><year>2024</year><volume>13</volume><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm13051327</pub-id><pub-id pub-id-type="pmcid">PMC10932454</pub-id><pub-id pub-id-type="pmid">38592149</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mansour</surname><given-names>HA</given-names></name><name name-style="western"><surname>Mahmoudzadeh</surname><given-names>R</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>J</given-names></name></person-group><article-title>Intraocular Fibrin Glue to Lower the Risk of Postoperative Vitreous Hemorrhage After Diabetic Pars Plana Vitrectomy</article-title><source>Retina</source><year>2023</year><volume>43</volume><fpage>2148</fpage><lpage>2152</lpage><pub-id pub-id-type="pmid">36731110</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/IAE.0000000000003597</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Guo</surname><given-names>B</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J</given-names></name><name name-style="western"><surname>Mei</surname><given-names>J</given-names></name><name name-style="western"><surname>Deng</surname><given-names>C</given-names></name><name name-style="western"><surname>Wu</surname><given-names>R</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Q</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Z</given-names></name></person-group><article-title>Effect of anti-vascular endothelial growth factor on early-stage post-vitrectomy macular edema in patients with proliferative diabetic retinopathy</article-title><source>BMC Ophthalmol</source><year>2024</year><volume>24</volume><fpage>398</fpage><pub-id pub-id-type="pmid">39243038</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12886-024-03634-z</pub-id><pub-id pub-id-type="pmcid">PMC11378450</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Luan</surname><given-names>R</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B</given-names></name><name name-style="western"><surname>Gong</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Shao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name></person-group><article-title>The Anatomic and Functional Outcomes of Ozurdex-Aided Vitrectomy in Proliferative Diabetic Retinopathy</article-title><source>Diabetes Metab Syndr Obes</source><year>2024</year><volume>17</volume><fpage>1199</fpage><lpage>1213</lpage><pub-id pub-id-type="pmid">38476345</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/DMSO.S445607</pub-id><pub-id pub-id-type="pmcid">PMC10929653</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Qu</surname><given-names>C</given-names></name><name name-style="western"><surname>Yan</surname><given-names>H</given-names></name></person-group><article-title>Network meta-analysis of intravitreal conbercept as an adjuvant to vitrectomy for proliferative diabetic retinopathy</article-title><source>Front Endocrinol (Lausanne)</source><year>2023</year><volume>14</volume><fpage>1098165</fpage><pub-id pub-id-type="pmid">36896181</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fendo.2023.1098165</pub-id><pub-id pub-id-type="pmcid">PMC9989469</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Damasceno</surname><given-names>NA</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>JAE</given-names></name><name name-style="western"><surname>Yannuzzi</surname><given-names>NA</given-names></name><name name-style="western"><surname>Flynn</surname><given-names>H Jr</given-names></name><name name-style="western"><surname>Maia</surname><given-names>M</given-names></name><name name-style="western"><surname>Damasceno</surname><given-names>EF</given-names></name><name name-style="western"><surname>Farah</surname><given-names>ME</given-names></name></person-group><article-title>Potential Risk Factors for Ocular Pain in Patients Undergoing Multiple Intravitreal Injections of Anti-Vascular Endothelial Growth Factor</article-title><source>Clin Ophthalmol</source><year>2024</year><volume>18</volume><fpage>1691</fpage><lpage>1699</lpage><pub-id pub-id-type="pmid">38863678</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/OPTH.S463016</pub-id><pub-id pub-id-type="pmcid">PMC11166166</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chauhan</surname><given-names>MZ</given-names></name><name name-style="western"><surname>Soliman</surname><given-names>MK</given-names></name><name name-style="western"><surname>Pace</surname><given-names>NL</given-names></name><name name-style="western"><surname>Mathis</surname><given-names>MR</given-names></name><name name-style="western"><surname>Schonberger</surname><given-names>RB</given-names></name><name name-style="western"><surname>Sallam</surname><given-names>AB</given-names></name></person-group><collab>MPOG Investigator Group</collab><article-title>Anesthesia Techniques for Vitreoretinal Surgery in the United States: A Report from the Multicenter Perioperative Outcomes Group Research Consortium</article-title><source>Am J Ophthalmol</source><year>2024</year><volume>267</volume><fpage>30</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">38871268</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajo.2024.06.010</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rohowetz</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Shaheen</surname><given-names>A</given-names></name><name name-style="western"><surname>Magraner</surname><given-names>M</given-names></name><name name-style="western"><surname>Flynn</surname><given-names>HW Jr</given-names></name><name name-style="western"><surname>Williams</surname><given-names>BK Jr</given-names></name><name name-style="western"><surname>Smiddy</surname><given-names>WE</given-names></name><name name-style="western"><surname>Sridhar</surname><given-names>J</given-names></name><name name-style="western"><surname>Russell</surname><given-names>JF</given-names></name><name name-style="western"><surname>Townsend</surname><given-names>JH</given-names></name><name name-style="western"><surname>Berrocal</surname><given-names>AM</given-names></name><name name-style="western"><surname>Albini</surname><given-names>T</given-names></name><name name-style="western"><surname>Yannuzzi</surname><given-names>NA</given-names></name></person-group><article-title>Surgical outcomes in concurrent sickle cell and diabetic retinopathy</article-title><source>Retina</source><year>2024</year><volume>44</volume><fpage>1560</fpage><lpage>1564</lpage><pub-id pub-id-type="pmid">39167577</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/IAE.0000000000004156</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thapa</surname><given-names>R</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>S</given-names></name><name name-style="western"><surname>Pradhan</surname><given-names>E</given-names></name><name name-style="western"><surname>Duwal</surname><given-names>S</given-names></name><name name-style="western"><surname>Paudyal</surname><given-names>G</given-names></name></person-group><article-title>Clinical Characteristics of Proliferative Diabetic Retinopathy and Outcome of Pars Plana Vitrectomy in Proliferative Diabetic Retinopathy</article-title><source>J Nepal Health Res Counc</source><year>2024</year><volume>22</volume><fpage>157</fpage><lpage>162</lpage><pub-id pub-id-type="pmid">39080953</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.33314/jnhrc.v22i01.4958</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>